Lung Cancer

In research published in Nicotine & Tobacco Research, lead author Charnita Zeigler-Johnson, PhD, MPH, Associate Director of Community Outreach and Engagement, studied the prevalence of smoking stigma among the African American/Black community.

The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

The FDA has approved frontline pembrolizumab plus chemotherapy for use in unresectable advanced or metastatic malignant pleural mesothelioma.

Shirish M. Gadgeel, MD, discusses long-term follow-up data from the MARIPOSA study for patients with EGFR-positive advanced non–small cell lung cancer.

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

The DUBLIN-3 trial showed plinabulin plus docetaxel improved survival in EGFR wild-type non–small cell lung cancer.